Our top pick for
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Haemonetics Corporation is a medical instruments & supplies business based in the US. Haemonetics Corporation shares (HAE) are listed on the NYSE and all prices are listed in US Dollars. Haemonetics Corporation employs 3,004 staff and has a trailing 12-month revenue of around 0.00.
|52-week range||$66.27 - $142.11|
|50-day moving average||$104.70|
|200-day moving average||$113.96|
|Wall St. target price||$117.43|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$2.12|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Valuing Haemonetics Corporation stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Haemonetics Corporation's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Haemonetics Corporation's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 32x. In other words, Haemonetics Corporation shares trade at around 32x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Haemonetics Corporation's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.9997. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Haemonetics Corporation's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Haemonetics Corporation's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $219.7 million.
The EBITDA is a measure of a Haemonetics Corporation's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||$883.9 million|
|Operating margin TTM||14.85%|
|Gross profit TTM||$487.8 million|
|Return on assets TTM||6.42%|
|Return on equity TTM||16.72%|
|Market capitalisation||$3.4 billion|
TTM: trailing 12 months
There are currently 2.0 million Haemonetics Corporation shares held short by investors – that's known as Haemonetics Corporation's "short interest". This figure is 17.4% up from 1.7 million last month.
There are a few different ways that this level of interest in shorting Haemonetics Corporation shares can be evaluated.
Haemonetics Corporation's "short interest ratio" (SIR) is the quantity of Haemonetics Corporation shares currently shorted divided by the average quantity of Haemonetics Corporation shares traded daily (recently around 414741.40127389). Haemonetics Corporation's SIR currently stands at 4.71. In other words for every 100,000 Haemonetics Corporation shares traded daily on the market, roughly 4710 shares are currently held short.
However Haemonetics Corporation's short interest can also be evaluated against the total number of Haemonetics Corporation shares, or, against the total number of tradable Haemonetics Corporation shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Haemonetics Corporation's short interest could be expressed as 0.04% of the outstanding shares (for every 100,000 Haemonetics Corporation shares in existence, roughly 40 shares are currently held short) or 0.0497% of the tradable shares (for every 100,000 tradable Haemonetics Corporation shares, roughly 50 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Haemonetics Corporation.
Find out more about how you can short Haemonetics Corporation stock.
We're not expecting Haemonetics Corporation to pay a dividend over the next 12 months.
Haemonetics Corporation's shares were split on a 2:1 basis on 2 December 2012. So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your Haemonetics Corporation shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for Haemonetics Corporation shares which in turn could have impacted Haemonetics Corporation's share price.
Over the last 12 months, Haemonetics Corporation's shares have ranged in value from as little as $66.27 up to $142.11. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Haemonetics Corporation's is 0.5014. This would suggest that Haemonetics Corporation's shares are less volatile than average (for this exchange).
Haemonetics Corporation, a healthcare company, provides hematology products and solutions. It operates through three segments: Plasma, Blood Center, and Hospital. The company offers automated plasma collection devices, related disposables, and software, including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and intravenous solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system. It also provides automated blood component and manual whole blood collection systems, such as MCS brand apheresis equipment to collect specific blood components from the donor; disposable whole blood collection and component storage sets; SafeTrace Tx and El-Dorado Donor donation and blood unit management systems; Hemasphere software that provides support for blood drive planning; and Donor Doc and e-Donor software to enhance the donor recruitment and retention. In addition, the company offers hospital products comprising TEG diagnostic systems that enables clinicians to assess the coagulation status of a patient at the point-of-care or laboratory setting; TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions; Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries; and BloodTrack, a suite of blood management and bedside transfusion solutions that combines software with hardware components, as well as an extension of the hospital's blood bank information system. It markets and sells its products through direct sales force, independent distributors, and sales representatives. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts.
Everything we know about the Krispy Kreme IPO, plus information on how to buy in.
Everything we know about the Day One Biopharmaceuticals IPO, plus information on how to buy in.
Everything we know about the Enact Holdings IPO, plus information on how to buy in.
Everything we know about the Solid Power IPO, plus information on how to buy in.
Everything we know about the Paymentus Holdings IPO, plus information on how to buy in.
Everything we know about the Qiniu Limited IPO, plus information on how to buy in.
Everything we know about the Qiniu Limited IPO, plus information on how to buy in.
Everything we know about the Ximalaya IPO, plus information on how to buy in.
Everything we know about the Zeta Global Holdings Corp IPO, plus information on how to buy in.
Everything we know about the Paycor HCM IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.